Related Experiment Video
Updated: Jun 3, 2025
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization
Chuchun Fang1,2,3, Xuewei Liu4,5,2, Chen Yu6
1Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Background:
Cancer-targeted therapies are progressively pivotal in oncological care. Observational studies underscore the emergence of cancer therapy-related cardiovascular toxicity (CTR-CVT), impacting patient outcomes. We aimed to investigate the causal relationship between different types of cancer-targeted therapies and cardiovascular disease (CVD) outcomes through a two-sample Mendelian randomization (MR) study.
Methods:
This genome-wide association study was conducted using a two-sample Mendelian randomization framework. Genetic instruments for drug target gene expression were extracted from the eQTLGen consortium (31684 individuals, 37 cohorts). Genome-wide association study (GWAS) summary statistics for 19 cardiovascular diseases were derived from the FinnGen database. Primary analysis was carried out using the summary-data-based MR (SMR) method, with sensitivity analysis for validation. Colocalization analysis identifies shared causal variants between exposure eQTLs and CVD-associated single-nucleotide polymorphisms (SNPs).
Results:
Among the 39 drug target genes, 8 were identified with detectable cis-eQTLs and were subsequently validated through positive control analysis for further investigation. In the SMR and sensitivity analyses, genetically proxied VEGFA inhibition showed significantly strong association with stroke (odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.09-1.26, p = 1.33 × 10- 5). Additionally, the inhibition of FGFR1, FLT1, and MAP2K2 exhibited suggestive association with corresponding cardiovascular disease outcomes. Nevertheless, only VEGFA expression and stroke shared a causal variant (93.6%), whereas FGFR1, MAP2K2, and FLT1 did not share causal variants with corresponding cardiovascular diseases in the colocalization analysis.
Conclusions:
This genetic association study revealed evidence supporting the genetic association between the use of VEGFA inhibitors and increased stroke risk, highlighting the need for enhanced pharmacovigilance. These findings underscore the delicate balance between cardiovascular toxicity risk and the benefits of cancer-targeted therapy.
Insights
Cancer-targeted therapies, like VEGFA inhibitors, are linked to increased stroke risk. Enhanced monitoring is crucial to balance cancer treatment benefits with cardiovascular risks.
Area of Science:
- Cardiovascular research
- Oncology
- Genetics
Background:
- Cancer-targeted therapies are crucial in oncology.
- Cancer therapy-related cardiovascular toxicity (CTR-CVT) is an emerging concern.
- Observational studies highlight CTR-CVT's impact on patient outcomes.
Purpose of the Study:
- To investigate the causal relationship between cancer-targeted therapies and cardiovascular disease (CVD) outcomes.
- Utilizing a two-sample Mendelian randomization (MR) study design.
- To identify specific genetic links between drug targets and CVD.
Main Methods:
- Employed a two-sample Mendelian randomization (MR) framework.
- Used genome-wide association study (GWAS) data from eQTLGen and FinnGen databases.
- Applied summary-data-based MR (SMR) and colocalization analyses for validation.
Main Results:
- Genetically proxied VEGFA inhibition showed a significant association with increased stroke risk (OR=1.17, P=1.33×10⁻⁵).
- Inhibitions of FGFR1, FLT1, and MAP2K2 suggested associations with CVD outcomes.
- Only VEGFA expression and stroke shared a causal variant, indicating a specific genetic link.
Conclusions:
- VEGFA inhibitors are genetically associated with an elevated risk of stroke.
- Findings emphasize the need for enhanced pharmacovigilance for cancer therapies.
- A careful balance between CTR-CVT and cancer treatment efficacy is essential.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:12Hazard Ratio
For example, in a clinical trial...
01:25Mutagenicity and Carcinogenicity